Patents by Inventor Lian G. Rajewski

Lian G. Rajewski has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9968553
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: December 21, 2017
    Date of Patent: May 15, 2018
    Assignees: SILVERGATE PHARMACAUTICALS, INC., UNIVERSITY OF KANSAS
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Publication number: 20180116954
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Inventors: Lian G. RAJEWSKI, Roger A. RAJEWSKI, John L. HASLAM, Kathleen HEPPERT, Michael C. BECKLOFF, Frank SEGRAVE, Robert MAURO, Peter COLABUONO
  • Patent number: 9855214
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: February 15, 2017
    Date of Patent: January 2, 2018
    Assignees: SILVERGATE PHARMACEUTICALS, INC, UNIVERSITY OF KANSAS
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Publication number: 20170181968
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: February 15, 2017
    Publication date: June 29, 2017
    Inventors: Lian G. RAJEWSKI, Roger A. RAJEWSKI, John L. HASLAM, Kathleen HEPPERT, Michael C. BECKLOFF, Frank SEGRAVE, Robert MAURO, Peter COLABUONO
  • Publication number: 20150258027
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: October 2, 2013
    Publication date: September 17, 2015
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Patent number: 8900629
    Abstract: The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: December 2, 2014
    Assignee: University of Kansas
    Inventors: Roger A. Rajewski, Lian G. Rajewski, John L. Haslam
  • Patent number: 8778366
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: July 15, 2014
    Assignees: University of Kanasas, Silvergate Pharmaceuticals, Inc.
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Publication number: 20140100260
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Application
    Filed: June 10, 2013
    Publication date: April 10, 2014
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Segrave, Robert Mauro, Peter Colabuono
  • Patent number: 8568747
    Abstract: Provided herein are stable enalapril powder compositions for oral liquid formulation. Also provided herein are methods of using enalapril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and asymptomatic left ventricular dysfunction.
    Type: Grant
    Filed: November 6, 2012
    Date of Patent: October 29, 2013
    Assignees: Silvergate Pharmaceuticals, Inc., University of Kansas
    Inventors: Lian G. Rajewski, Roger A. Rajewski, John L. Haslam, Kathleen Heppert, Michael C. Beckloff, Frank Seagrave, Robert Mauro, Peter Colabuono
  • Publication number: 20130005831
    Abstract: The present disclosure provides rapidly dissolving oral capsules and films comprising pullulan, a plasticizer, and a dissolution enhancing agent.
    Type: Application
    Filed: December 22, 2011
    Publication date: January 3, 2013
    Applicant: UNIVERSITY OF KANSAS
    Inventors: Roger A. Rajewski, Lian G. Rajewski, John L. Haslam
  • Patent number: 7235258
    Abstract: Sustained-release compositions for delivering therapeutic concentrations of isovaleramide, isovaleric acid, and certain structurally related compounds are provided for the treatment for a variety of pathological conditions, including epilepsy and spasticity, which are ameliorated by effecting a modulation of CNS activity. The ability of the compositions to sustain relatively constant levels of the drug at a therapeutic dose in the serum for extended periods of time enables a once or twice daily administration schedule.
    Type: Grant
    Filed: October 19, 2000
    Date of Patent: June 26, 2007
    Assignee: NPS Pharmaceuticals, Inc.
    Inventors: David S. Wells, Lian G. Rajewski, Thomas B. Marriott, James D. Pipkin, John L. Haslam